Septarna [SEPN] vs Regeneron [REGN] Detailed Stock Comparison

Septarna Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Septarna Inc. wins in 2 metrics, Regeneron Pharmaceuticals, Inc. wins in 14 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Septarna Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) N/A 18.00 N/A
Price-to-Book Ratio 2.89 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 6.19 9.51 Septarna Inc.
PEG Ratio -12.68 -4.80 Regeneron Pharmaceuticals, Inc.
EV/EBITDA -9.35 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) -106.37% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) -66.44% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -12.19% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -9.59% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $109.67M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 226.49% 25.39% Septarna Inc.
Price-to-Sales Ratio (TTM) 24.11 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $740.38M $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 16.11 4.95 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) $1 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-1.10 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) N/A 0.40 N/A
Short % of Float 9.41% 2.55% Regeneron Pharmaceuticals, Inc.

Septarna Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

SEPN
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Septarna Inc.2.04%2.55%23.09%8.60%15.07%9.19%
Regeneron Pharmaceuticals, Inc.2.66%-1.40%-12.73%-19.27%-14.47%-20.27%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Septarna Inc.226.49%41.12%41.12%41.12%41.12%41.12%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: Septarna Inc. vs Regeneron Pharmaceuticals, Inc.

MetricSEPNREGN
Market Information
Market Cap i$1.11B$80.98B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i420,760642,495
90 Day Avg. Volume i311,777617,765
Last Close$30.55$618.95
52 Week Range$9.70 - $32.63$476.49 - $821.11
% from 52W High-6.37%-24.62%
All-Time High$32.63 (Feb 25, 2026)$1,211.20 (Aug 26, 2024)
% from All-Time High-6.37%-48.90%
Growth Metrics
Quarterly Revenue Growth112.76%0.03%
Quarterly Earnings Growth112.76%-0.08%
Financial Health
Profit Margin (TTM) i-1.06%0.31%
Operating Margin (TTM) i-0.66%0.23%
Return on Equity (TTM) i-0.12%0.15%
Debt to Equity (MRQ) i6.199.51
Cash & Liquidity
Book Value per Share (MRQ)$8.52$304.65
Cash per Share (MRQ)$8.71$83.86
Operating Cash Flow (TTM) i$110.19M$4.98B
Levered Free Cash Flow (TTM) i$18.81M$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Septarna Inc. vs Regeneron Pharmaceuticals, Inc.

MetricSEPN (Apr 26, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/A18.00
Forward P/E i-12.6814.21
PEG Ratio i-12.68-4.80
Price to Sales (TTM) i24.115.50
Price to Book (MRQ) i2.892.45
Market Capitalization
Market Capitalization i$1.11B$80.98B
Enterprise Value i$740.38M$70.98B
Enterprise Value Metrics
Enterprise to Revenue i16.114.95
Enterprise to EBITDA i-9.3516.72
Risk & Other Metrics
Beta iN/A0.40
Book Value per Share (MRQ) i$8.52$304.65

Financial Statements Comparison: Septarna Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSEPN (2025)REGN (2025)
Revenue/Sales i45.95M14.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i0.0%14.6%
Gross Profit iN/A12.24B
Gross Margin i0.0%85.4%
Research & Development i97.58M5.85B
Operating Income (EBIT) i-80.80M3.70B
Operating Margin i-175.8%25.8%
EBITDA i-91.69M5.00B
EBITDA Margin i-199.5%34.8%
Pre-Tax Income i-48.87M5.23B
Pre-Tax Income % of Revenue i-106.3%36.5%
Income Tax i12,000725.80M
Income Tax % of Revenue i0.0%5.1%
Net Income (Profit) i-48.88M4.50B
Profit Margin i-106.4%31.4%

Balance Sheet & Liquidity Metrics

MetricSEPN (2025)REGN (2025)
Cash & Equivalents i120.72M3.12B
Total Current Assets i410.96M18.02B
Total Current Assets % of Revenue i894.4%125.7%
Total Current Liabilities i86.93M4.37B
Total Current Liabilities % of Revenue i189.2%30.5%
Long-Term Debt i21.41M2.71B
Long-Term Debt % of Revenue i46.6%18.9%
Total Shareholders Equity i381.93M31.26B
Retained Earnings i-167.25M35.80B
Retained Earnings % of Revenue i-364.0%249.6%
Property, Plant & Equipment i27.84M1.54B

Cash Flow Statement Comparison

MetricSEPN (2025)REGN (2025)
Operating Cash Flow i125.56M6.30B
Operating Cash Flow % of Revenue i273.2%43.9%
Capital Expenditures i-518,0000
Free Cash Flow i109.67M3.77B
FCF Margin i238.7%26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase i-1,000-3.97B

Short Interest & Institutional Ownership Analysis

MetricSEPNREGN
Shares Short i2.46M2.55M
Short Ratio i8.854.46
Short % of Float i9.41%2.55%
Shares Outstanding i44.81M105.72M
Float Shares i22.90M98.55M
% Held by Insiders i3.14%1.98%
% Held by Institutions i102.97%91.08%
% Held by Public i-6.11%6.94%

Dividend Analysis & Yield Comparison: Septarna Inc. vs Regeneron Pharmaceuticals, Inc.

MetricSEPNREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026